Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

GENOME EDITING

‘Hit and run’ therapy averts macular degeneration

Subretinal delivery of lentiviruses bearing Cas9 mRNA and a guide RNA targeting the Vegfa gene reduces the development of choroidal neovascularization in a mouse model of wet age-related macular degeneration.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Lentiviral delivery of Cas9 mRNA and a Vegfa-targeting gRNA to retinal epithelium largely prevents the development of wet age-related macular degeneration in mice.

References

  1. Prel, A. et al. Mol. Ther. Methods Clin. Dev. 2, 15039 (2015).

    Article  Google Scholar 

  2. Ling, S. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-020-00656-y (2021).

  3. Michel, G., Yu, Y., Chang, T. & Yee, J. K. Mol. Ther. 18, 1814–1821 (2010).

    Article  CAS  Google Scholar 

  4. Cai, Y. et al. Nucleic Acids Res. 42, e28 (2014).

    Article  CAS  Google Scholar 

  5. He, C. et al. Gene Ther. 21, 759–766 (2014).

    Article  CAS  Google Scholar 

  6. Cai, Y., Bak, R. O. & Mikkelsen, J. G. eLife 3, e01911 (2014).

    Article  Google Scholar 

  7. Lyu, P., Wang, L. & Lu, B. Life (Basel) 10, 366 (2020).

    Google Scholar 

  8. Yin, D. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-020-00781-8 (2021).

  9. Arthur, L. O. et al. Science 258, 1935–1938 (1992).

    Article  CAS  Google Scholar 

  10. Rulli, S. J.Jr et al. J. Virol. 81, 6623–6631 (2007).

    Article  CAS  Google Scholar 

  11. Nguyen, G. N. et al. Nat. Biotechnol. 39, 47–55 (2021).

    Article  CAS  Google Scholar 

  12. Anzalone, A. V., Koblan, L. W. & Liu, D. R. Nat. Biotechnol. 38, 824–844 (2020).

    Article  CAS  Google Scholar 

  13. Wesselhoeft, R. A., Kowalski, P. S. & Anderson, D. G. Nat. Commun. 9, 2629 (2018).

    Article  Google Scholar 

  14. Li, A. et al. Mol. Ther. 28, 1432–1441 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dirk Grimm.

Ethics declarations

Competing interests

D.G. is a co-founder and shareholder of AaviGen GmbH. F.B. and D.G. have filed patent applications related to CRISPR technologies and gene delivery via adeno-associated viruses.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bubeck, F., Grimm, D. ‘Hit and run’ therapy averts macular degeneration. Nat Biomed Eng 5, 132–133 (2021). https://doi.org/10.1038/s41551-021-00690-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41551-021-00690-4

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research